Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Pharmacogenetics and personal genomes.

Wagner MJ.

Per Med. 2009 Nov 1;6(6):643-652.

2.

Characterizing and interpreting genetic variation from personal genome sequencing.

Johansson AC, Feuk L.

Methods Mol Biol. 2012;838:343-67. doi: 10.1007/978-1-61779-507-7_17.

PMID:
22228021
3.

Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Shah RR.

Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1617-38. Review.

4.

Pharmacogenetic application in drug development and clinical trials.

Shi MM, Bleavins MR, de la Iglesia FA.

Drug Metab Dispos. 2001 Apr;29(4 Pt 2):591-5.

5.

Expanding role of pharmacogenomics in the management of cardiovascular disorders.

Yip VL, Pirmohamed M.

Am J Cardiovasc Drugs. 2013 Jun;13(3):151-62. doi: 10.1007/s40256-013-0024-5. Review.

PMID:
23579966
6.

Pharmacogenetics: a general review on progress to date.

Daly AK.

Br Med Bull. 2017 Dec 1;124(1):65-79. doi: 10.1093/bmb/ldx035.

PMID:
29040422
7.

DraGnET: software for storing, managing and analyzing annotated draft genome sequence data.

Duncan S, Sirkanungo R, Miller L, Phillips GJ.

BMC Bioinformatics. 2010 Feb 22;11:100. doi: 10.1186/1471-2105-11-100.

9.

Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment.

Drögemöller BI, Wright GE, Niehaus DJ, Emsley R, Warnich L.

Pharmacogenet Genomics. 2013 Dec;23(12):666-74. doi: 10.1097/FPC.0000000000000006.

PMID:
24141736
10.

The limits of genome-wide methods for pharmacogenomic testing.

Gamazon ER, Skol AD, Perera MA.

Pharmacogenet Genomics. 2012 Apr;22(4):261-72. doi: 10.1097/FPC.0b013e328350ca5f.

11.

Pharmacogenetics: from discovery to patient care.

Shin J, Kayser SR, Langaee TY.

Am J Health Syst Pharm. 2009 Apr 1;66(7):625-37. doi: 10.2146/ajhp080170. Review.

PMID:
19299369
12.

Sequencing technologies and genome sequencing.

Pareek CS, Smoczynski R, Tretyn A.

J Appl Genet. 2011 Nov;52(4):413-35. doi: 10.1007/s13353-011-0057-x. Epub 2011 Jun 23. Review.

13.

Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now.

Weitzel KW, Cavallari LH, Lesko LJ.

Pharm Res. 2017 Aug;34(8):1551-1555. doi: 10.1007/s11095-017-2163-x. Epub 2017 May 2.

PMID:
28466392
14.

Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies.

Aardema MJ, MacGregor JT.

Mutat Res. 2002 Jan 29;499(1):13-25. Review.

PMID:
11804602
16.

Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance.

Brazell C, Freeman A, Mosteller M.

Br J Clin Pharmacol. 2002 Mar;53(3):224-31. Review.

17.

A clinical approach to pharmacogenetics.

de Graaff LC, van Schaik RH, van Gelder T.

Neth J Med. 2013 Apr;71(3):145-52.

18.

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.

Schwartz JB, Kane L, Moore K, Wu AH.

J Am Med Dir Assoc. 2011 Nov;12(9):633-8. doi: 10.1016/j.jamda.2010.12.006. Epub 2011 Jan 26.

PMID:
21450231
19.

Next-generation sequencing technologies: breaking the sound barrier of human genetics.

Bahassi el M, Stambrook PJ.

Mutagenesis. 2014 Sep;29(5):303-10. doi: 10.1093/mutage/geu031. Review.

PMID:
25150023
20.

Genome variation discovery with high-throughput sequencing data.

Dalca AV, Brudno M.

Brief Bioinform. 2010 Jan;11(1):3-14. doi: 10.1093/bib/bbp058. Epub 2010 Jan 6.

PMID:
20053733

Supplemental Content

Support Center